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Data are required for a meaningful approach to quality and from different sources for decision modeling and some 
cost-conscious cardiovascular care. How to identify the possible solutions are discussed in this summary of the 
types of data available and their sources, advantages and Working Group on Data for Cardiovascular Modeling. 
limitations to their use, issues involved in combining data (J Am Co11 Cardiol1989;14:6OA_4A) 
The challenge of the 1990s is to mold the multiple sources of 
partial information that are available concerning cardiovas- 
cular disease into a meaningful whole for the delivery of 
quality and cost-conscious cardiovascular care. This review 
attempts to identify the types of data available and some of 
their sources and the advantages and limitations in their use 
in order to discuss concerns in combining different data 
sources for decision modeling, and then to propose solutions 
for these concerns. The types of data bases providing 
information include insurance claims data bases, random- 
ized clinical trial data bases, intramural research registries, 
health care management data bases, clinical research data 
bases and archival data bases. The focus and function of 
each data base are the key to understanding its advantages 
and limitations for use in decision modeling. The method- 
ologic problems of each are discussed. This discussion 
expands on the previous work of Pryor et al. (1). 
Types of Data Bases Available 
The generic types of data available for use in cardiovas- 
cular research are shown in Table 1. These data bases all 
have varying amounts and quality of data that can be used 
for decision modeling in cardiovascular disease; the focus 
and function of the data base provide a useful framework for 
understanding its advantages and limitations. 
Insurance claims data bases. These are typified by those 
from Blue Cross/Blue Shield (BC/BS) and the Health Care 
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Financing Administration’s Medicare records. These data 
bases include populations defined by the organization paying 
for the service. The Health Care Financing Administration’s 
involvement with all patients >65 years provides a complete 
age cohort for cardiovascular modeling. The types of infor- 
mation available from such data bases are typified from the 
Uniform Billing-82 (UB-82), and limited to demographics 
(age and gender), diagnoses, procedure, length of stay and 
discharge status. The focus of the claims data base is a 
definite population defined by economic factors. Its primary 
economic function has resulted in the inclusion of little 
information about patient risk or prognostic factors. Also, 
the quality of the clinical data is sometimes an issue. 
Randomized clinical trial data bases. These provide very 
detailed and focused information, usually directed to just 
one therapy comparison for a narrowly defined population of 
interest. Randomized clinical trial data bases are costly to 
collect and time-limited in scope. The design of the trial 
requires that the therapies available to the randomized 
patients remain stable for the duration of the trial, limiting 
their usefulness in evaluating emerging technologies. Be- 
cause the function of the data base is research, randomized 
clinical trial data are the easiest to use (including combined 
treatment comparisons), the most complete and the more 
accurate, albeit on a limited population. 
Intramural research data bases. These are typically reg- 
istries sponsored by the National Institutes of Health, al- 
though they may also be sponsored by medical device or 
pharmaceutical manufacturers. The focus of the intramural 
research data base is a single procedure or diagnosis. Its 
function is to collect early efficacy or outcome information. 
Data are collected voluntarily by participating institutions. 
There may be considerable variation in the quality of data 
collected at different centers. Examples of recent intramural 
research data bases in cardiovascular disease are the Na- 
tional Heart, Lung, and Blood Institute-sponsored Percuta- 
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Table 1. Types of Data Bases for Cardiovascular Decision Making 
Insurance claims 
Randomized clinical trial 
Intramural research registries 
Administrative/health care management 
Clinical research 
“Archival” 
Quality review 
neous Transluminal Coronary Angioplasty Registry (2) and 
Balloon Valvuloplasty Registry. 
Administrative or health care management data bases. 
These usually focus on patients as they relate to an institu- 
tion or group practice and are oriented toward costs and 
charges. The function of these data bases is to provide the 
billing services for the institution. Typically, these data 
bases contain information similar to that of the claims data 
base, with more detail to allow itemized billing. The quality 
of the data in these data bases is often poor. 
Clinical data bases. These are formed when data items 
concerning patients are routinely recorded and coupled with 
outcome descriptors (1). They are distinguished from admin- 
istrative data bases by the extent of medical information 
collected. For example, clinical data bases may or may not 
include charge information, depending on the exact focus 
and function of the data base. The clinical data base becomes 
a clinical research data base when research methods to 
improve quality are used to collect the data. Because clinical 
research data bases collect data for both clinical care and 
research activities, different parts of the data base may have 
different levels of care used to collect the data. In addition, 
clinical research data bases do not have focused hypotheses, 
and the information that is collected prospectively is a 
composite of variables, including those thought to be clini- 
tally useful and those of known research value. To respond 
to evolving technologies, the data bases are dynamic, adding 
new items as they are thought to be important, and no longer 
collecting old data as they come into disuse. Clinical re- 
search data bases are ongoing, requiring long-term institu- 
tional commitments. 
“Archival” data bases. These collect data prospectively 
for future needs, but do not have a focused goal (as do 
randomized clinical trials) or immediate function (as does a 
claims data base). They are usually utilized in retrospective 
clinical research studies, helping to identify appropriate 
groups of patients. The quality of the data is variable, and 
can be quite good if maintained by interested, research- 
oriented personnel. The most well known example of an 
archival data base is the Mayo Clinic Data Base (3,4), 
created as a disease log when the Mayo Clinic first opened 
and subsequently reorganized and computerized to include 
disease diagnoses made by all physicians practicing in Olm- 
sted County, Minnesota. 
Quality review data bases. These are formed by various 
peer review organizations and third party payers performing 
diagnostic-related group audits. The Joint Commission for 
Accreditation of Healthcare Organizations maintains data 
bases for its accreditation process. High quality methods are 
used to abstract the data, but the overall quality is limited by 
the retrospective method, and access to these data bases is 
often severely restricted. 
Role of Data Bases 
Evaluating data bases in relation to goals. Data bases can 
be used to generalize from the individual to the patient 
population. The advantages and limitations of each data base 
and the goals of the analysis determine the maximal degree 
to which this generalization is appropriate. Characteristics of 
Table 2. Matrix for Evaluating Factors Affecting Role of Data Base for Decision Making 
Focus of Data Base 
Data Base Qualities 
No. of variables 
Error rate 
Spectrum 
(broad/narrow) 
Generalizability 
Completeness 
Subjectivity 
Maturity of field 
Flexibility 
Types of items 
Measures of outcome 
Hardware/software 
issues 
Randomized 
Clinical 
Trial 
Epidemiologic 
Clinical 
Research 
Direct 
Patient 
Care 
Support 
Payments 
Support 
Collections 
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the data base structure and manner of storage determine the 
ease with which information can be used. Table 2 displays a 
sample matrix for considering the value of a data base in 
decision modeling. The qualities of each data base need to be 
examined and related to the goals of modeling. Specific goals 
may require that other qualities be evaluated in addition to 
those listed. 
Decisions about patients or policy need to be based on 
conclusions drawn from data. Particularly in chronic dis- 
eases such as ischemic heart disease, characterized by long 
periods of time between disease onset, interventions and 
outcome, it is difficult for practitioners, even experts, to 
couple the long-term process of care to eventual outcome. 
Data bases may provide the data, as long as the results of the 
analysis are interpreted in light of the advantages and 
disadvantages of the data source. Randomized clinical trial 
data bases provide the best models on focused questions 
pertaining to restricted patient populations. Nonrandomized 
clinical trial data bases can be used to complement the data 
from randomized clinical trials, confirming findings, filling in 
gaps and extending findings. Clinical research data bases, as 
distinguished from other nonrandomized clinical trial data 
bases, can also be used to evaluate evolving technologies. 
Challenges in modeling across time. Data bases are used 
to examine time trends by modeling across time. Modeling 
across time has several challenges, including linking patient 
records (potentially from different data bases), timeliness of 
analysis, validation and control of results, amount of data to 
be dealt with (technically and conceptually), consistency of 
definitions over time, bias inherent in each type of data base 
as a result of its focus and function, and cost of data 
collection. Despite these limitations, such analyses may be 
the first to clarify important advances in therapy. 
Table 3. Current Data Bases With Data on Cardiovascular Disease 
Randomized clinical trials 
Coronary Artery Surgery Study (CASS) (5) 
Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Trial (6) 
Thrombolysis in Myocardial Infarction (TIMI) Trial (7) 
Bypass and Angioplasty Randomized Intervention (BARI) Trial 
Veterans Administration Coronary Artery Bypass Graft Trial (8) 
European Coronary Surgery Study (9) 
Pharmaceutical trials 
Insurance claims 
Health Care Finance Administration 
Blue Cross/Blue Shield 
Other third party payers 
Intramural research registries-National Institutes of Health 
Percutaneous transluminal coronary angioplasty (2) 
Balloon valvuloplasty 
Administrative/health care management 
Hospitals/group practices/health maintenance organizations 
(with automated billing systems) 
Clinical research 
Cleveland Clinic (IO) 
Duke Database for Cardiovascular Disease (11) 
University of California at San Diego (12) 
Regenstrief Medical Record (13) 
CASS Registry (5) 
ArchivaUregistry 
Mayo Clinic (diagnosis-population-based) (3.4) 
Seattle Heart Watch Registry 
Baptist Memorial Hospital (Memphis, Tennessee) Cardiac Disease 
Registry 
University of Alabama Registry (14) 
Emory University Registry (15) 
Quality review 
Joint Committee on Accreditation of Hosoitals 
Issues in Combining Data Bases 
Because no single data base contains all of the items that 
might be needed for decision modeling in cost-conscious 
cardiovascular care, there is a need to combine data across 
sources. Consistent definition of data items is the most 
significant problem to be addressed. Common definitions are 
needed to effectively combine data sources and facilitate 
clear communication in publications. Standard definitions 
are the first step in resolving whether and to what extent data 
can be trusted. 
Data Bases for Cardiovascular Disease 
The data bases listed in Table 3 are known to contain data 
that can be useful in cardiovascular disease decision model- 
ing. These data bases may or may not be accessible to 
outside collaboration for a variety of reasons (see the report 
by Fisher in this issue). To evaluate each data base for use 
for a particular modeling goal requires the investigator to 
consider potential strengths and weaknesses, as depicted in 
the matrix shown in Table 2. 
The data bases just described collect many different types 
of information. Information categories include demograph- 
ics, history and physical data, problems, diagnostic proce- 
dures, treatments, outcomes, costs and charges (direct and 
indirect), providers and quality of life. However, no single 
data base collects all of this information. 
New data bases are needed for decision modeling in 
emerging technologies, in outpatient groups and with a 
population-based focus. 
To develop standard definitions, three goals must be met. 
First, standard definitions need to differentiate between the 
conceptual item being defined and the method for measuring 
it. As an example of the differentiation needed, for the 
cognitive item “heart output,” one can technically measure 
left ventricular contractility, ejection fraction (qualitatively 
or quantitatively) or cardiac output (by two or more meth- 
ods). Second, definitions need to be able to change over time 
because technical measurement capabilities are evolving 
rapidly. Third, for standards to work, there must be reasons 
for abiding by the standards, incentives in the form of easier 
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Randomized Clinical Trial 
Administrative File 
Amount of Data 
Figure 1. Schematic representation of the extent of data from 
different sources for the patient population being studied. 
sharing and better communication or pressures in the form of 
requirement for publication, grants or reimbursement. 
Quality control of the data being collected for different 
types of data bases presents additional challenges. Tracer 
variables or subsets of patients can be chosen for extensive 
quality control, with publication of the quality level. Quality 
control standards must take into account that the focus and 
function of the data base determine the degree of quality 
control required. 
With common definitions and an understanding of the 
information in the data base, a merging of data such as that 
shown in Figure 1, might be attained. Certain basic measure- 
ments would be collected for all patents to provide a basic 
description of the study population (denominator data). 
Other data bases would collect other types of information, 
with varying degrees of completeness and extent. Areas in 
Figure 1 that overlap with each other would use the same 
definitions and degree of quality assurance. This might allow 
the extrapolation of results from data bases with more 
extensive information to those with less extensive data. 
Conclusions. There is clear agreement on the need for 
data bases for decision modeling in cardiovascular care, 
although how these should be developed and supported is 
less clear. Data bases of varying focus and function need to 
be combined, as do those of common focus and function, but 
with different patient populations. Decisions need to be 
based on conclusions drawn from reliable data. If we cannot 
provide the data, decisions will still be made. Elegant 
methods used to structure decisions or policies based on 
opinion do not obviate the need for modeling these decisions 
on real experiences. Statistical techniques can be used to 
reduce the effect of observational biases inherent in any data 
base, but there must be sufficient prognostic variables cou- 
pled with an appropriate pathophysiologic understanding to 
adjust for severity of illness. 
Common definitions are the first step in allowing common 
needs to be met. The American College of Cardiology 
Norms Committee is one logical choice to establish a defi- 
nition of clinical attributes for a “core” of items for cardio- 
vascular modeling. The definitions should be subject to 
continuing review to allow for innovation in measurement 
and the evolution of the field. Similarly, the definitions 
should differentiate between the purely cognitive definition 
and that part tied to the technology of measuring. The 
definition should be favorably received and used by the 
entire medical community. 
New data bases are needed for decision modeling in 
emerging technologies, in outpatient groups and with a 
population-based focus. 
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